BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression

Fang, Wei; Tang, Le; He, Yi; Wu, Yingfen; Shi, Lei; Xiong, Fang; Gong, Zhaojian; Guo, Can; Li, Xiayu; Liao, Qianjin; Zhang, Wenling; Ni, Qianxi; Luo, Jiayou; Li, Xiaoling; Li, Yong; Peng, Cong; Chen, Xiang; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang

doi:10.1038/s41419-018-0409-0

Cited by 72 publications

(58 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, individualized treatment has gradually gained attention, and the individualized treatment of cancer has been increasingly promoted [58][59][60][61][62][63]. As the gene with the highest mutation rate in PTC, the BRAF gene is of great significance for the development of PTC and is widely used in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

Self Cite

View full text Add to dashboard Cite

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion:The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer are common malignant tumors that show high rates of metastasis . Moreover, the malignant progression and high mortality rates associated with these tumors are related to their insidious onset, frequent metastasis and recurrence, and poor prognosis . Treatment on the basis of early diagnosis is still the main approach for achieving long‐term cancer‐free survival .…”

Section: Discussionmentioning

confidence: 99%

“…P < 0.01 to their insidious onset, frequent metastasis and recurrence, and poor prognosis. [29][30][31] Treatment on the basis of early diagnosis is still the main approach for achieving long-term cancer-free survival. [32][33][34][35][36] Although many biomarkers of malignant tumors are currently used in the clinical setting, all of these biomarkers have limitations.…”

Section: Discussionmentioning

confidence: 99%

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

et al. 2019

Self Cite

View full text Add to dashboard Cite

Novel diagnostic and prognostic biomarkers of cancers are needed to improve precision medicine. Circular RNAs act as important regulators in cancers at the transcriptional and posttranscriptional levels. The circular RNA circMAN1A2 is highly expressed in nasopharyngeal carcinoma according to our previous RNA sequencing data; however, the expression and functions of circMAN1A2 in cancers are still obscure. Therefore, in this study, we evaluated the expression of circMAN1A2 in the sera of patients with nasopharyngeal carcinoma and other malignant tumors and analyzed its correlations with clinical features and diagnostic values. The expression levels of circMAN1A2 were detected by quantitative real‐time PCR, and the correlations of clinical features with circMAN1A2 expression were analyzed by χ2 tests. Receiver operating characteristic curves were used to evaluate the clinical applications of circMAN1A2. The results showed that circMAN1A2 was upregulated in nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer, with areas under the curves of 0.911, 0.779, 0.734, 0.694, and 0.645, respectively, indicating the good diagnostic value of circMAN1A2. Overall, our findings suggested that circMAN1A2 could be a serum biomarker for malignant tumors, providing important insights into diagnostic approaches for malignant tumors. Further studies are needed to elucidate the mechanisms of circMAN1A2 in the pathogenesis of cancer.

show abstract

“…Malignant cell proliferation is one of the hallmarks of tumor cells [82][83][84][85][86]. Research has shown that c-Myc can promote the transcription of positive cell cycle regulatory factors, such as E2F transcription factors, cyclin D1, and cyclin-dependent kinase 4 (CDK4).…”

Section: Pvt1 Participates In the Proliferation-related Signaling Patmentioning

confidence: 99%

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

Jin

Wang

Zhang

et al. 2019

Cell. Mol. Life Sci.

Self Cite

112

View full text Add to dashboard Cite

Numerous studies have shown that non-coding RNAs play crucial roles in the development and progression of various tumor cells. Plasmacytoma variant translocation 1 (PVT1) mainly encodes a long non-coding RNA (lncRNA) and is located on chromosome 8q24.21, which constitutes a fragile site for genetic aberrations. PVT1 is well-known for its interaction with its neighbor MYC, which is a qualified oncogene that plays a vital role in tumorigenesis. In the past several decades, increasing attention has been paid to the interaction mechanism between PVT1 and MYC, which will benefit the clinical treatment and prognosis of patients. In this review, we summarize the coamplification of PVT1 and MYC in cancer, the positive feedback mechanism, and the latest promoter competition mechanism of PVT1 and MYC, as well as how PVT1 participates in the downstream signaling pathway of c-Myc by regulating key molecules. We also briefly describe the treatment prospects and research directions of PVT1 and MYC.

show abstract

BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression

Cited by 72 publications

References 40 publications

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

Contact Info

Product

Resources

About